65 related articles for article (PubMed ID: 19596943)
1. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas.
Fujimoto J
Anticancer Res; 2009 Jul; 29(7):2665-9. PubMed ID: 19596943
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
Willmott LJ; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
4. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of angiogenic factors in uterine cervical cancer.
Landt S; Wehling M; Heidecke H; Jeschke S; Korlach S; Stöblen F; Schmid P; Blohmer JU; Lichtenegger W; Sehouli J; Kümmel S
Anticancer Res; 2011 Aug; 31(8):2589-95. PubMed ID: 21778309
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy for osteosarcoma.
Quan GM; Choong PF
Cancer Metastasis Rev; 2006 Dec; 25(4):707-13. PubMed ID: 17160710
[TBL] [Abstract][Full Text] [Related]
7. Novel chemotherapy approaches for cervical cancer.
Movva S; Rodriguez L; Arias-Pulido H; Verschraegen C
Cancer; 2009 Jul; 115(14):3166-80. PubMed ID: 19452541
[TBL] [Abstract][Full Text] [Related]
8. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
Wong ML; Prawira A; Kaye AH; Hovens CM
J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.
Naidoo S; Raidoo DM
Oncol Rep; 2009 Aug; 22(2):285-93. PubMed ID: 19578768
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
Cohen-Jonathan Moyal E
Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
[TBL] [Abstract][Full Text] [Related]
11. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
12. Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency.
Lippi G; Franchini M; Salvagno GL; Guidi GC
Cancer Treat Rev; 2007 Aug; 33(5):427-36. PubMed ID: 17442497
[TBL] [Abstract][Full Text] [Related]
13. [Role of sentinel node biopsy in early-stage cervical cancer in the therapeutic strategy].
Lousquy R; Delpech Y; Barranger E
Gynecol Obstet Fertil; 2009 Oct; 37(10):827-33. PubMed ID: 19766048
[TBL] [Abstract][Full Text] [Related]
14. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
Greenberg JI; Cheresh DA
Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenesis inhibitors and radiation therapy: from biology to clinical practice].
Mazeron R; Azria D; Deutsch E
Cancer Radiother; 2009 Oct; 13(6-7):568-73. PubMed ID: 19695932
[TBL] [Abstract][Full Text] [Related]
16. [Surgical lymph-node evaluation in cervical cancer].
Mathevet P
Cancer Radiother; 2009 Oct; 13(6-7):499-502. PubMed ID: 19660975
[TBL] [Abstract][Full Text] [Related]
17. Visualization, quantification and therapeutic evaluation of angiogenic vessels in cancer by synchrotron microangiography.
Sekka T; Volchikhina SA; Tanaka A; Hasegawa M; Tanaka Y; Ohtani Y; Tajima T; Makuuchi H; Tanaka E; Iwata Y; Sato S; Hyodo K; Ando M; Umetani K; Kubota M; Tanioka K; Mori H
J Synchrotron Radiat; 2000 Nov; 7(Pt 6):361-7. PubMed ID: 16609222
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
19. Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients.
Li TS; Kubo M; Ueda K; Murakami M; Ohshima M; Kobayashi T; Tanaka T; Shirasawa B; Mikamo A; Hamano K
Circulation; 2009 Sep; 120(11 Suppl):S255-61. PubMed ID: 19752376
[TBL] [Abstract][Full Text] [Related]
20. [Anti-angiogenic drugs].
Sato Y
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1072-5. PubMed ID: 19620794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
